GLP-1 side effect symptoms

Nausea on GLP-1 medications

30-50%in pivotal trials

Nausea is the most common GLP-1 side effect. It peaks in the first 4-8 weeks of treatment, typically after each dose increase, and resolves as the body adapts to delayed gastric emptying.

Diarrhea on GLP-1 medications

10-15%in pivotal trials

Diarrhea affects ~10-15% of GLP-1 patients during initial titration. Usually self-limited and resolves within 4-8 weeks. Hydration is the primary management concern.

Constipation on GLP-1 medications

7-11%in pivotal trials

Constipation affects ~7-11% of GLP-1 patients. Result of slowed gastric/intestinal motility + reduced food intake. Usually responds well to hydration + fiber + activity.

Fatigue on GLP-1 medications

5-11%in pivotal trials

Fatigue affects ~5-11% of GLP-1 patients. Usually result of reduced calorie intake during early titration + underlying GI side effects + body adapting to weight loss.

Headache on GLP-1 medications

10-14%in pivotal trials

Headache affects ~10-14% of GLP-1 patients during titration. Often dehydration-driven or related to dropping blood-sugar levels in non-diabetic patients.

Hair loss on GLP-1 medications

3-7%in pivotal trials

Hair shedding affects ~3-7% of GLP-1 patients. Almost always telogen effluvium (stress-related shedding from rapid weight loss), NOT permanent hair loss. Resolves within 6-12 months.

Gallbladder issues on GLP-1 medications

6%in pivotal trials

Gallbladder disease (gallstones, cholecystitis) affects ~1.5-2.6% of GLP-1 patients in trials. Risk is highest during rapid weight loss in the first 6-12 months.

Mood changes on GLP-1 medications

FDA conducted post-marketing surveillance on potential suicidal ideation signals (2023-2024); no causal link confirmed. Some patients report mild mood/anxiety changes, often resolving with weight stabilization.

Dizziness on GLP-1 medications

3-8%in pivotal trials

Dizziness on GLP-1 medications usually reflects dehydration or hypoglycemia (if combined with insulin/sulfonylurea), not a direct drug effect. Most cases resolve with better fluid intake and meal timing.

Dry mouth on GLP-1 medications

3-5%in pivotal trials

Dry mouth (xerostomia) affects a small share of GLP-1 patients, mostly during titration. Usually caused by reduced fluid intake, not direct salivary effects.

Brain fog on GLP-1 medications

5-8%in pivotal trials

Cognitive slowness or "brain fog" is reported by a subset of GLP-1 patients, most commonly during titration. Usually traceable to undereating, dehydration, or sleep disruption — not a direct neurologic effect.

Heart palpitations on GLP-1 medications

15-20%in pivotal trials

Mild heart-rate increase (5-10 bpm) is documented across the GLP-1 class. Most patients adapt; persistent palpitations or rates above 100 bpm at rest warrant evaluation.

Increased thirst on GLP-1 medications

10-15%in pivotal trials

Polydipsia (increased thirst) on GLP-1s usually reflects insufficient water intake catching up — patients who weren't drinking enough notice thirst as their body recalibrates.

Taste changes on GLP-1 medications

2-5%in pivotal trials

Some patients report metallic, sour, or muted taste during early titration. Usually transient — resolves within 4-8 weeks of stable dose. Dysgeusia rarely persists.

Sleep changes on GLP-1 medications

8-15%in pivotal trials

GLP-1 medications can affect sleep through multiple paths: delayed gastric emptying disrupts late-night digestion; reduced appetite changes eating schedules; weight loss can improve or worsen sleep apnea. Insomnia and vivid dreams are both reported.

Eye irritation on GLP-1 medications

3-8%in pivotal trials

Mild dry-eye symptoms can occur during GLP-1 therapy, usually due to systemic dehydration. Recent FDA labels added warnings for NAION (rare optic-nerve event) — distinct from common dry-eye.

Joint pain on GLP-1 medications

2-5%in pivotal trials

Mild joint discomfort is occasionally reported on GLP-1s, typically appearing during rapid weight loss phases. Most often reflects lean-mass loss + biomechanical adjustment to changing body composition, not a direct drug effect.

Back pain on GLP-1 medications

3-7%in pivotal trials

Back pain on GLP-1s typically reflects biomechanical changes from rapid weight loss or shifted activity patterns. Pre-existing back conditions may worsen during initial weight loss phases before stabilizing.

Cold intolerance on GLP-1 medications

10-20%in pivotal trials

Feeling cold more easily on GLP-1 medications is commonly reported during weight loss — reflects reduced metabolic rate from lower body mass + thermogenic adaptation, not a direct drug effect.

Dry skin on GLP-1 medications

8-15%in pivotal trials

Dry skin during GLP-1 therapy typically reflects dehydration + reduced food intake (lower water from food). Significant weight loss can also cause skin laxity that feels drier.

Menstrual changes on GLP-1 medications

15-25%in pivotal trials

Significant weight loss on GLP-1s often improves menstrual irregularity, particularly in PCOS or obesity-related anovulation. Some patients also notice cycle changes during titration weeks — usually transient.

Body temperature changes on GLP-1 medications

8-15%in pivotal trials

Some patients on GLP-1s report feeling either colder or warmer than usual. Most reflect metabolic adaptation to weight loss. Persistent thermoregulation issues may signal thyroid involvement.

Blood pressure changes on GLP-1 medications

20-30%in pivotal trials

GLP-1 medications typically lower blood pressure by 3-5 mmHg through weight loss + direct effects. Patients on antihypertensives may experience hypotension and require dose reduction.

Reduced food cravings on GLP-1 medications

60-80%in pivotal trials

Reduced food cravings (often called "food noise quieting") is a hallmark GLP-1 effect — not technically a side effect but a desired pharmacologic outcome. Patients describe intrusive food thoughts dramatically decreasing.

Muscle loss on GLP-1 medications

25-40%in pivotal trials

Some of the weight lost on GLP-1 medications is lean muscle, not just fat. Body-composition studies suggest roughly 25-40% of total weight lost can be lean mass when protein intake and resistance training are neglected. It is largely preventable and is not a direct drug toxicity.

Stomach paralysis (gastroparesis) on GLP-1 medications

GLP-1 medications deliberately slow stomach emptying — that is part of how they curb appetite. In a small number of people this becomes severe, persistent delayed emptying (gastroparesis). In 2023 the FDA added a warning about ileus (a halt in intestinal movement) to semaglutide labeling.

GLP-1 medications and alcohol

Many people on GLP-1 medications notice they want to drink less — the drugs act on the same brain reward pathways involved in alcohol craving, an effect now under active study. There is no absolute ban on alcohol, but it can worsen nausea and dehydration and (with diabetes medications) raise the risk of low blood sugar.

Injection-site reactions on GLP-1 medications

3-10%in pivotal trials

Mild redness, itching, or a small lump at the injection site affects a minority of people using injectable GLP-1 medications and usually settles within a few days. Rotating injection sites and proper technique prevent most reactions.